- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT05135559
Badanie naukowe dotyczące skuteczności koncyzumabu u osób z hemofilią A lub B z inhibitorami lub bez nich (Explorer10)
Otwarte badanie oceniające skuteczność, bezpieczeństwo i farmakokinetykę profilaktyki koncyzumabu u dzieci w wieku poniżej 12 lat z hemofilią A lub B z inhibitorami lub bez
This study will test how well a new medicine called concizumab works for participants who have haemophilia A or B with or without inhibitors. The purpose is to show that concizumab can prevent bleeds and is safe to use.
Participants will have to inject the study medicine every day under the skin with a pen-injector.
The study will last for at least 2 years and up to about 4 years. The length of time the participant will be in the study depends on if the study medicine will be available for purchase in their country.
Przegląd badań
Status
Interwencja / Leczenie
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 3
Rozszerzony dostęp
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Gauteng
-
Parktown, Johannesburg, Gauteng, Afryka Południowa, 2193
- Charlotte Maxeke Johannesburg Academic Hospital
-
-
-
-
-
Algiers, Algieria, 16000
- Haematology and Blood Bank Department
-
Constantine, Algieria, 25000
- CHU Constantine BEN BADIS/ Hematology department
-
-
-
-
-
Banja Luka, Bośnia i Hercegowina, 78000
- University Clinical Center of Republic Srpska (545)
-
Tuzla, Bośnia i Hercegowina, 75000
- University Clinical Centre Tuzla
-
-
-
-
-
Plovdiv, Bułgaria, 4002
- UMHAT Sveti Georgi EAD, Plovdiv, Clinic of Pediatrics
-
Sofia, Bułgaria, 1527
- UMHAT Tsaritsa Yoanna - ISUL EAD, Pediatric clinical hematology and oncology
-
Varna, Bułgaria, 9010
- UMHAT Sveta Marina EAD, Clinic of Pediatric Clinical Hematology and Oncology
-
-
-
-
-
Tallinn, Estonia, 13419
- Tallinn Children's Hospital
-
-
-
-
-
Chambéry, Francja, 73000
- Centre Hospitalier Metropole Savoie
-
Le Kremlin-Bicêtre, Francja, 94275
- Ap-Hp-Hopital de Bicetre-1
-
Paris, Francja, 75015
- AP-HP-HOPITAL NECKER_Service d'hématologie
-
-
-
-
-
Athens, Grecja, GR-11527
- Aghia Sophia Childrens' Hospital
-
Thessaloniki, Grecja, GR 54642
- 'Ippokrateio' General Hospital of Thessaloniki
-
Thessaloniki, Grecja, 54642
- 'Ippokrateio' General Hospital of Thessaloniki
-
-
-
-
-
Barcelona, Hiszpania, 08035
- Hospital Vall d'Hebron
-
Madrid, Hiszpania, 28046
- Hospital Universitario La Paz
-
Málaga, Hiszpania, 29009
- Hospital Regional Universitario de Málaga
-
-
Murcia
-
El Palmar, Murcia, Hiszpania, 30120
- Hospital Virgen de la Arrixaca - Hematología
-
-
-
-
Assam
-
Guwahati, Assam, Indie, 781032
- Guwahati Medical College
-
-
Gujarat
-
Surat, Gujarat, Indie, 395002
- Nirmal Hospital Pvt. Ltd.
-
-
Maharashtra
-
Kolhāpur, Maharashtra, Indie, 416005
- SSSH_Dept. of Clinical Haematology & Haemato Oncology
-
Mumbai, Maharashtra, Indie, 400012
- Seth GS Medical College & KEM Hospital
-
Mumbai, Maharashtra, Indie, 400022
- K.J Somaiya Hospital and Research Centre
-
Mumbai, Maharashtra, Indie, 400066
- MCGM - Comprehensive Thalassemia Care
-
Pune, Maharashtra, Indie, 411004
- Sahyadri Super Speciality Hospital
-
-
Odisha
-
Cuttack, Odisha, Indie, 753007
- S.C.B. Medical College
-
-
Rajasthan
-
Jaipur, Rajasthan, Indie, 302004
- J K Lon Hospital
-
-
Uttar Pradesh
-
Noida, Uttar Pradesh, Indie, 201303
- Post Graduate Institute of Child Health
-
-
Uttart Pradesh
-
Lucknow, Uttart Pradesh, Indie, 226014
- SGPGI
-
-
-
-
-
Kanagawa, Japonia, 216-8511
- St. Marianna University School of Medicine Hospital_Pediatrics
-
Saitama, Japonia, 330-8777
- Saitama Children's Med Centre_Hematology-Oncology
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V6H 3V4
- BC Children's Hospital
-
-
Ontario
-
Hamilton, Ontario, Kanada, L8N 3Z5
- McMaster Children's Hospital
-
-
-
-
-
Beirut, Liban, 961
- Saint George Hospital University Medical Center
-
Tripoli, Liban, 1434
- Hospital Nini
-
-
-
-
-
Vilnius, Litwa, LT-08406
- Centre of Oncology and Hematology, Vilnius University
-
-
-
-
-
Skopje, Macedonia Północna, 1000
- PHI University Clinic for Children's Diseases Skopje
-
-
-
-
Kuala Lumpur
-
Kampung Baru, Kuala Lumpur, Malezja, 50300
- Hospital Tunku Azizah
-
-
Pulau Pinang
-
George Town, Pulau Pinang, Malezja, 10450
- Hospital Pulau Pinang
-
-
Sarawak
-
Kuching, Sarawak, Malezja, 93586
- Sarawak General Hospital
-
-
Terengganu
-
Kuala Terengganu, Terengganu, Malezja, 20400
- Hospital Sultanah Nur Zahirah
-
-
-
-
-
Oslo, Norwegia, 0372
- Klinisk forskningspost
-
-
-
-
-
Gdansk, Polska, 80-952
- Uniwersyteckie Centrum Kliniczne
-
Lublin, Polska, 20-093
- Uniwersytecki Szpital Dzieciecy, Dzial Krwiolecznictwa
-
Warsaw, Polska, 02-091
- Uniwersyteckie Centrum Kliniczne WUM
-
-
Lower Silesian Voivodeship
-
Wroclaw, Lower Silesian Voivodeship, Polska, 50-556
- Uniwersytecki Szpital Kliniczny im. J.Mikulicza-Radeckiego
-
-
-
-
-
Bucharest, Rumunia, 022328
- Clinic of Haematology, Fundeni Clinical Institute
-
Cluj-Napoca, Rumunia, 400177
- Spitalul Clinic de Urgenta pentru Copii Cluj Napoca
-
Oradea, Rumunia, 410469
- Spitalul Clinic Judetean De Urgenta Bihor
-
-
-
-
California
-
San Diego, California, Stany Zjednoczone, 92123
- Rady Childrens Hosp San Diego
-
-
Colorado
-
Aurora, Colorado, Stany Zjednoczone, 80045
- University of Colorado Hospital
-
-
Florida
-
Orlando, Florida, Stany Zjednoczone, 32806
- Arnold Palmer Children's Hospital
-
Orlando, Florida, Stany Zjednoczone, 32827
- Nemours Child Orlando Hem/Onc.
-
-
Georgia
-
Augusta, Georgia, Stany Zjednoczone, 30912
- Augusta Univ/Childrens Hosp-GA
-
Savannah, Georgia, Stany Zjednoczone, 31404
- Memorial Health University Medical Center
-
-
Illinois
-
Chicago, Illinois, Stany Zjednoczone, 60611
- Childrens Hospital of Chicago
-
-
Indiana
-
Indianapolis, Indiana, Stany Zjednoczone, 46260
- Indiana Hemophilia-Thromb Ctr
-
-
Louisiana
-
New Orleans, Louisiana, Stany Zjednoczone, 70121
- Ochsner Clinic Foundation
-
New Orleans, Louisiana, Stany Zjednoczone, 70118
- Children's Hosp-New Orleans
-
-
Missouri
-
Kansas City, Missouri, Stany Zjednoczone, 64108
- The Children's Mercy Hospital
-
-
Nebraska
-
Omaha, Nebraska, Stany Zjednoczone, 68114
- Children's Nebraska
-
-
North Carolina
-
Greenville, North Carolina, Stany Zjednoczone, 27834
- ECU Sickle Cell Comp Clinic
-
-
Ohio
-
Columbus, Ohio, Stany Zjednoczone, 43205
- Nationwide Children's Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stany Zjednoczone, 19134
- St Christopher Hosp for Child
-
-
Tennessee
-
Nashville, Tennessee, Stany Zjednoczone, 37232
- Monroe Carell Jr. Children's Hospital at Vanderbilt
-
-
Texas
-
Fort Worth, Texas, Stany Zjednoczone, 76104
- Cook Children's Hospital-Hematology-Oncology
-
Houston, Texas, Stany Zjednoczone, 77030
- Texas Children's Hospital_Houston
-
-
Virginia
-
Charlottesville, Virginia, Stany Zjednoczone, 22908
- Pediatrics Hematology/Oncology Clinic Battle Building
-
-
-
-
-
Gothenburg, Szwecja, 413 46
- Sahlgrenska US - Koagulationscentrum
-
-
-
-
-
Bangkok, Tajlandia, 10400
- Ramathibodi Hospital
-
Bangkok, Tajlandia, 10330
- King Chulalongkorn Memorial Hospital_Bangkok_0
-
Bangkok, Tajlandia, 10700
- Siriraj Hospital - Hematology and Oncology
-
Bangkok, Tajlandia, 10330
- King Chulalongkorn Memorial Hospital_Pediatric Hematology-Oncology
-
-
Mueang Distirct,
-
Ubon Ratchathani, Mueang Distirct,, Tajlandia, 34000
- Sunpasitthiprasong Hospital_Pediatrics Department
-
-
-
-
-
Adana, Turcja (Türkiye), 01130
- Acibadem Adana Hastanesi
-
Adana, Turcja (Türkiye), 01130
- Acıbadem Adana Hastanesi-Hematoloji
-
Izmir, Turcja (Türkiye), 35100
- Ege Universitesi Tip Fakultesi
-
Izmir, Turcja (Türkiye), 35100
- Ege Üniversitesi Hastanesi- Hematoloji
-
Samsun, Turcja (Türkiye), 55139
- Ondokuz Mayis University Medical Faculty Ped. Haematology
-
Samsun, Turcja (Türkiye), 55139
- Ondokuz Mayıs Üniversitesi Hastanesi - Hematoloji
-
-
Beşevler/Ankara
-
Ankara, Beşevler/Ankara, Turcja (Türkiye), 06500
- Gazi University
-
Ankara, Beşevler/Ankara, Turcja (Türkiye), 06500
- Gazi Üniversitesi Hastanesi- Hematoloji
-
-
-
-
-
Catania, Włochy, 95123
- A.O.U policlinico "G. Rodolico-San Marco"
-
Florence, Włochy, 50134
- Dipartimento di Ematologia Univ. Firenze
-
Padova, Włochy, 35128
- Azienda Ospedaliera di Padova _
-
Parma, Włochy, 43126
- Azienda Ospedaliera-Universitaria Parma
-
-
-
-
-
Birmingham, Zjednoczone Królestwo, B4 6NH
- Birmingham Children's Hospital
-
Bristol, Zjednoczone Królestwo, BS2 8BJ
- University Hospitals Bristol & Weston NHS Foundation Trust
-
London, Zjednoczone Królestwo, WC1N 3HR
- Great Ormond Street Hospital for Children
-
London, Zjednoczone Królestwo, SE1 7EH
- Evelina London Children's Hospital - Haemophilia
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dziecko
- Dorosły
- Starszy dorosły
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
-
Informed consent/assent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
-
Diagnosis of congenital severe haemophilia A (FVIII below 1%) or moderate/severe congenital haemophilia B (FIX (coagulation factor IX) below or equal to 2%), or congenital haemophilia with inhibitors.
-
For arm 1 only: Male aged below 12 years of age at the time of signing informed consent.
-
For arm 1 only: Patients with inhibitors (haemophilia A with inhibitors or haemophilia B with inhibitors)
- Patients with HAwI (haemophilia A with inhibitors) with historical medical records of a total of at least 26 weeks of on-demand treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products) within the last 52 weeks prior to enrolment (For patients below 1 year of age that have been diagnosed with haemophilia <1 year prior to enrolment, historical medical records from time of diagnosis will suffice as long as medical records of a total of at least 26 weeks of relevant treatment is available).
- Patients with HBwI (haemophilia B with inhibitors) with historical medical records of a total of at least 26 weeks of on-demand treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products) within the last 52 weeks prior to enrolment (For patients below 1 year of age that have been diagnosed with haemophilia <1 year prior to enrolment, historical medical records from time of diagnosis will suffice as long as medical records of a total of at least 26 weeks of relevant treatment is available).
- Patients with HBwI regardless of the regimen and duration of previous haemophilia treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products)
-
For arm 1 only: Patients without inhibitors (haemophilia A or haemophilia B)
- Patients with historical medical records of at least 52 weeks of on-demand treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products; Surgery related PPX or short-term PPX (e.g., in relation to a severe bleed) is not allowed) during the last year prior to enrolment and with at least 3 documented treated bleeds (For participants less than (<) 2 years of age there is no limitation for number of documented treated bleeds in the medical history) during this period
- Patients with historical medical records of a total of at least 26 weeks of PPX (prophylaxis) treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products) within the last 52 weeks prior to enrolment (For patients below 1 year of age that have been diagnosed with haemophilia <1 year prior to enrolment, historical medical records from time of diagnosis will suffice as long as medical records of a total of at least 26 weeks of relevant treatment is available)
-
For arm 2 only: Male patients (regardless of age) previously treated with concizumab via compassionate use.
Exclusion Criteria:
- Known or suspected hypersensitivity to study intervention or related products.
- Known inherited or acquired coagulation disorder other than congenital haemophilia.
- Ongoing or planned Immune Tolerance Induction treatment.
- History of thromboembolic disease (aIncludes arterial and venous thrombosis including myocardial infarction, pulmonary embolism, cerebral infarction/thrombosis, deep vein thrombosis, other clinically significant thromboembolic events and peripheral artery occlusion.). Current clinical signs of or treatment for thromboembolic disease. Patients who in the judgement of the investigator are considered at high risk of thromboembolic events (Thromboembolic risk factors could include, but are not limited to, hypercholesterolemia, diabetes mellitus, hypertension, obesity, smoking, family history of thromboembolic events, arteriosclerosis, other conditions associated with increased risk of thromboembolic events).
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nielosowe
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Concizumab-naïve patients
Concizumab-naïve participants below 12 years of age at the time of consent/assent |
Participants in Arm 1 will be assigned to concizumab prophylaxis starting with a loading dose on treatment day 0 followed by daily injections of an individual maintenance dose. Participants in Arm 2 will be assigned to concizumab prophylaxis with daily injections of an individual maintenance dose. |
|
Eksperymentalny: Patients coming from compassionate use
Patients previously treated with concizumab via compassionate use, either on an individual patient basis or through the concizumab compassionate use programme NN7415-4807 |
Participants in Arm 1 will be assigned to concizumab prophylaxis starting with a loading dose on treatment day 0 followed by daily injections of an individual maintenance dose. Participants in Arm 2 will be assigned to concizumab prophylaxis with daily injections of an individual maintenance dose. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
Ramy czasowe: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients treated on demand during at least the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
Ramy czasowe: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of all bleeding episodes (spontaneous and traumatic)
Ramy czasowe: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated spontaneous bleeding episodes
Ramy czasowe: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated joint bleeding episodes
Ramy czasowe: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated bleeding episodes in baseline target joints
Ramy czasowe: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients treated on-demand during at least the last 52 weeks prior enrolment: Number of all bleeding episodes (spontaneous and traumatic)
Ramy czasowe: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients treated on-demand during at least the last 52 weeks prior enrolment: Number of treated spontaneous bleeding episodes
Ramy czasowe: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients treated on-demand at least the last 52 weeks prior enrolment: Number of treated joint bleeding episodes
Ramy czasowe: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients treated on-demand at least the last 52 weeks prior enrolment: Number of treated bleeding episodes in baseline target joints
Ramy czasowe: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
Ramy czasowe: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of all bleeding episodes (spontaneous and traumatic)
Ramy czasowe: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated spontaneous bleeding episodes
Ramy czasowe: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated joint bleeding episodes
Ramy czasowe: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated bleeding episodes in baseline target joints
Ramy czasowe: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Concizumab-naïve pateints - Number of treatment emergent adverse events, reported both separately for inhibitor and non-inhibitor patients and combined
Ramy czasowe: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of event(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Number of thromboembolic events, reported both separately for inhibitor and non-inhibitor patients and combined
Ramy czasowe: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of event(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Number of hypersensitivity type reactions, reported both separately for inhibitor and non-inhibitor patients and combined
Ramy czasowe: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of event(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Number of injection site reactions, reported both separately for inhibitor and non-inhibitor patients and combined
Ramy czasowe: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of event(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Number of patients who develop antibodies to concizumab - yes/no, reported both separately for inhibitor and non-inhibitor patients and combined
Ramy czasowe: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of patient(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Number of treatment emergent adverse events, reported both separately for inhibitor and non-inhibitor patients and combined
Ramy czasowe: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of event(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Concizumab plasma concentrations prior to dosing, reported both separately for inhibitor and non-inhibitor patients and combined
Ramy czasowe: Week 32
|
Measured in ng/mL |
Week 32
|
|
Peak thrombin generation prior to dosing, reported both separately for inhibitor and non-inhibitor patients and combined
Ramy czasowe: Week 32
|
Measured in nM |
Week 32
|
|
Free TFPI concentration prior to dosing, reported both separately for inhibitor and non-inhibitor patients and combined
Ramy czasowe: Week 32
|
Measured in ng/mL |
Week 32
|
|
Pre-dose (trough) concizumab plasma concentration (Ctrough), reported both separately for inhibitor and non-inhibitor patients and combined
Ramy czasowe: Prior to the concizumab administration at week 20
|
Measured in ng/mL |
Prior to the concizumab administration at week 20
|
|
Maximum concizumab plasma concentration (Cmax), reported both separately for inhibitor and non-inhibitor patients and combined
Ramy czasowe: From 0 to 24 hours where 0 is the time of the concizumab dose at week 20
|
Measured in ng/mL |
From 0 to 24 hours where 0 is the time of the concizumab dose at week 20
|
|
Area under the concizumab plasma concentration-time curve (AUC), reported both separately for inhibitor and non-inhibitor patients and combined
Ramy czasowe: From 0 to 24 hours where 0 is the time of the concizumab dose at week 20
|
Measured in ng*hr/mL |
From 0 to 24 hours where 0 is the time of the concizumab dose at week 20
|
Współpracownicy i badacze
Sponsor
Śledczy
- Dyrektor Studium: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- NN7415-4616
- U1111-1247-7330 (Inny identyfikator: World Health Organization (WHO))
- 2020-000504-11 (Numer EudraCT)
- jRCT2031220097 (Identyfikator rejestru: JAPIC)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .